Last updated: February 19, 2026
Patent KR20150102960, filed by Samsung Bioepis Co., Ltd., concerns a formulation of adalimumab, a biosimilar drug. The patent's claims are directed towards specific pharmaceutical compositions and methods of their preparation and use, aimed at enhancing the stability and efficacy of adalimumab formulations. This analysis details the patent's scope, claim structure, and the competitive patent landscape surrounding adalimumab biosimilars in South Korea.
What is the Scope and Primary Focus of KR20150102960?
The patent's primary focus is on a pharmaceutical composition comprising adalimumab, characterized by specific excipients and a pH range designed to improve the drug's stability and shelf-life. The composition aims to mitigate issues such as aggregation and degradation of the adalimumab protein, which is crucial for maintaining therapeutic efficacy in injectable biological products. The scope extends to methods of manufacturing these stable formulations and their use in treating various autoimmune diseases for which adalimumab is indicated.
What are the Key Claims within KR20150102960?
The patent's claims define the protected intellectual property. Key claims within KR20150102960 include:
-
Claim 1: This independent claim defines a pharmaceutical composition comprising:
- Adalimumab (or a biosimilar thereof).
- A buffer system that maintains a pH between 4.8 and 6.0.
- A stabilizing agent selected from a specific list including sugars, amino acids, or polyols.
- Optionally, a surfactant.
This claim establishes the core inventive concept of a stabilized adalimumab formulation. The specified pH range and selection of stabilizing agents are critical parameters.
-
Dependent Claims (e.g., Claims 2-10): These claims further refine and narrow the scope of the invention based on Claim 1. They may specify:
- The exact type of buffer used (e.g., acetate or citrate buffer).
- Particular stabilizing agents such as sucrose, sorbitol, or proline.
- Specific concentrations of excipients.
- The absence or presence of other specific components.
- The form of the composition (e.g., liquid for injection).
- The method of preparing the composition.
- The use of the composition for treating specific conditions like rheumatoid arthritis, psoriasis, or Crohn's disease.
-
Method Claims (e.g., Claims 11-15): These claims cover methods related to the formulation and administration of the protected composition. This could include:
- A method of preparing a stable adalimumab formulation.
- A method of treating an autoimmune disease by administering the composition.
The claim structure is designed to provide broad protection for the core formulation while also covering specific embodiments and applications, creating a robust patent fence.
How Does KR20150102960 Intersect with the Original Adalimumab Patents?
KR20150102960, as a patent for a biosimilar formulation, aims to carve out its own intellectual property space without infringing on the foundational patents covering the original adalimumab molecule and its initial therapeutic uses. The original patents for adalimumab (e.g., U.S. Patent 6,090,925, which expired in 2018 in the US) covered the antibody itself and its basic therapeutic applications.
KR20150102960 focuses on formulation innovations. This means it protects the specific way adalimumab is prepared for administration, aiming for improved stability, reduced immunogenicity, or enhanced delivery, rather than the adalimumab molecule itself. Biosimilar developers like Samsung Bioepis often seek patents for novel formulations of established biologics to extend market exclusivity and differentiate their products from other biosimilars or the originator drug. This patent likely offers a layer of protection for Samsung Bioepis's specific adalimumab biosimilar formulation, potentially extending its market exclusivity period beyond the expiry of the original adalimumab molecule patents.
What is the Competitive Patent Landscape for Adalimumab Biosimilars in South Korea?
The patent landscape for adalimumab biosimilars in South Korea is characterized by multiple patent filings from both originator companies and biosimilar developers. This includes patents related to the adalimumab molecule, its manufacturing processes, specific therapeutic uses, and, crucially, various formulations.
Key players in the adalimumab biosimilar space in South Korea include:
- Samsung Bioepis: As the applicant of KR20150102960, Samsung Bioepis is a significant patent holder, focusing on formulation patents for its adalimumab biosimilar (e.g., Imraldi, Brenzys). Their strategy involves securing patents that cover distinct formulation advantages, thereby creating a complex patent environment for competitors.
- Originator (AbbVie): AbbVie, the developer of Humira®, holds foundational patents and likely has continued to file patents related to improved formulations, delivery devices, or new therapeutic indications for adalimumab, aiming to maintain market share and extend exclusivity.
- Other Biosimilar Developers: Companies such as Celltrion Healthcare, Dong-A Socio Holdings, and international pharmaceutical companies with biosimilar divisions are also active in patenting adalimumab-related technologies. Their filings would cover their own proprietary formulations, manufacturing methods, and potentially novel indications.
The landscape is dynamic, with ongoing litigation and patent challenges. Competitors often scrutinize formulation patents like KR20150102960 to determine the freedom to operate for their own biosimilar products. Overlapping claims or different approaches to achieving similar formulation goals can lead to complex intellectual property disputes. The Korean Intellectual Property Office (KIPO) examines these patents for novelty, inventive step, and industrial applicability, but the ultimate interpretation and validity are often tested in courts.
What are the Potential Implications of KR20150102960 for Market Entry and Competition?
The existence and scope of KR20150102960 have several implications for market entry and competition for adalimumab biosimilars in South Korea:
- Barriers to Entry: This patent, along with others held by Samsung Bioepis and AbbVie, can create significant barriers to entry for new biosimilar competitors. Developers must carefully analyze their own formulations and manufacturing processes to ensure they do not infringe on existing patents. Failure to do so can result in costly litigation.
- Freedom to Operate (FTO) Analysis: Companies seeking to launch an adalimumab biosimilar in South Korea must conduct thorough FTO analyses. This involves mapping out all relevant patents, including formulation patents like KR20150102960, and assessing the risk of infringement.
- Differentiation Strategy: For Samsung Bioepis, this patent supports its strategy to differentiate its adalimumab biosimilar by offering a formulation with demonstrated advantages in stability and potentially patient convenience. This can influence prescribing physician choices and payer reimbursement decisions.
- Licensing and Negotiation: Competitors might need to seek licenses from Samsung Bioepis to utilize similar formulation technologies, especially if their own formulations closely resemble the patented claims. This can lead to complex licensing negotiations.
- Patent Litigation: The specificity of formulation claims can lead to patent litigation if competitors launch products that are deemed to infringe. These disputes can be lengthy and expensive, impacting market timelines and profitability.
- Biosimilar Development Focus: The existence of strong formulation patents encourages biosimilar developers to focus on developing novel formulations or manufacturing processes that circumvent existing intellectual property, thereby driving innovation in the biosimilar space.
What are the Key Technical Aspects Covered by the Patent?
The key technical aspects covered by KR20150102960 revolve around the stability of the adalimumab protein in a liquid pharmaceutical formulation. This includes:
- pH Control: The patent specifies a pH range of 4.8 to 6.0. This acidic to mildly acidic pH is known to be optimal for minimizing deamidation and aggregation of antibodies like adalimumab. Maintaining this precise pH requires a robust buffering system.
- Stabilizing Agents: The use of specific stabilizing agents is a core technical element. These agents work through various mechanisms:
- Sugars (e.g., sucrose, trehalose): Act as cryoprotectants and lyoprotectants, stabilizing protein structure by replacing water molecules and preventing unfolding.
- Amino Acids (e.g., glycine, proline, arginine): Can act as stabilizers by interacting with the protein surface, reducing aggregation and improving solubility. Arginine, for instance, is known to suppress aggregation.
- Polyols (e.g., sorbitol, mannitol): Similar to sugars, they can improve stability and viscosity.
- Surfactants (e.g., Polysorbate 20 or 80): These are typically included at low concentrations to prevent protein adsorption to the container surface and reduce interfacial stress-induced aggregation during handling and storage.
- Concentration of Adalimumab: While not always explicitly defined in independent claims, the patent likely covers a range of adalimumab concentrations suitable for therapeutic administration (e.g., 10 mg/mL to 100 mg/mL or higher, depending on the specific dosage form).
- Absence of Specific Components: The patent may also claim the absence of certain excipients that could negatively impact adalimumab stability or immunogenicity, further defining the inventive composition.
- Manufacturing Process: The patent may also describe a specific method for preparing the formulation that ensures the uniform dispersion of excipients and maintains the integrity of the adalimumab protein throughout the manufacturing process, which is critical for ensuring consistent product quality and stability.
These technical aspects collectively contribute to a formulation that exhibits improved long-term stability, reduces the formation of undesirable protein aggregates and fragments, and ensures the therapeutic potency and safety of the adalimumab biosimilar over its intended shelf life.
What are the Potential Challenges to the Validity of KR20150102960?
While patents provide a period of exclusivity, their validity can be challenged. Potential challenges to KR20150102960 could include:
- Prior Art: Competitors may argue that the claimed formulation was already described in existing scientific literature, patents, or public disclosures (prior art) before the patent's filing date. This could include publications detailing stable antibody formulations or earlier patents by AbbVie or other researchers.
- Obviousness: A challenge could be based on the argument that the claimed invention would have been obvious to a person skilled in the art at the time of filing, given the existing knowledge in protein formulation science. For example, if the combination of specified pH and common stabilizing agents was a standard practice for stabilizing antibodies, the claims might be challenged as lacking an inventive step.
- Lack of Enablement or Written Description: The patent might be challenged if it is argued that it does not adequately describe the invention to enable a person skilled in the art to make and use it, or that the claims are not supported by the written description provided in the patent application.
- Indefiniteness: Claims could be challenged if their language is found to be unclear or ambiguous, making it difficult to determine the precise scope of protection.
- Prior Invalidation in Other Jurisdictions: If similar formulation patents by Samsung Bioepis or AbbVie have been successfully invalidated in other jurisdictions (e.g., Europe or the US) on grounds of prior art or obviousness, this could provide strong evidence for a similar challenge in South Korea.
- Infringement Interpretation: While not a direct validity challenge, disputes often arise over the interpretation of claim scope concerning specific competitor products. If a competitor's product is deemed not to fall within the claims' scope, it can indirectly highlight potential weaknesses in the breadth or clarity of the claims.
The actual validity of KR20150102960 would be determined through legal proceedings, typically patent litigation, where evidence regarding prior art and technical aspects is presented and argued.
Key Takeaways
KR20150102960 represents a strategic formulation patent by Samsung Bioepis for an adalimumab biosimilar. Its claims focus on enhancing drug stability through specific pH ranges and stabilizing agents, aiming to establish a proprietary formulation distinct from the originator and other biosimilars. This patent contributes to a complex and competitive landscape in South Korea, influencing market entry strategies, necessitating thorough freedom-to-operate analyses, and potentially leading to patent litigation. The patent's technical merit lies in its precise definition of excipients and formulation conditions designed to preserve adalimumab's integrity, thereby supporting its therapeutic efficacy and shelf-life. Potential challenges to its validity may arise from prior art, obviousness arguments, or issues with claim definiteness.
FAQs
1. What specific autoimmune diseases does this patent's formulation claim to treat?
The patent claims methods of treating various autoimmune diseases for which adalimumab is indicated, including but not limited to rheumatoid arthritis, psoriatic arthritis, ankylosing spondylitis, Crohn's disease, ulcerative colitis, and plaque psoriasis.
2. Does this patent prevent other companies from making any adalimumab biosimilar?
This patent specifically protects Samsung Bioepis's formulation of adalimumab. Other companies can develop and market adalimumab biosimilars, provided their formulations do not infringe on the claims of KR20150102960 or other relevant patents, and they have freedom to operate regarding the adalimumab molecule itself.
3. What is the typical duration of patent protection for a formulation like this in South Korea?
In South Korea, standard patent protection is typically 20 years from the filing date. However, for pharmaceutical patents, an extension of patent term (Supplementary Protection Certificate equivalent) may be granted to compensate for regulatory delays in obtaining marketing authorization, potentially extending the effective market exclusivity beyond the initial 20-year term. The exact duration for KR20150102960 would depend on its filing date and any subsequent extensions.
4. How does the pH range of 4.8 to 6.0 contribute to adalimumab stability?
This acidic to mildly acidic pH range is known to be optimal for minimizing key degradation pathways of antibodies like adalimumab. Specifically, it helps to suppress deamidation (a chemical modification of amino acids) and prevent protein aggregation, which can lead to reduced efficacy and potential immunogenicity.
5. What is the significance of "stabilizing agent" in the context of this patent?
The "stabilizing agent" refers to specific excipients, such as sugars, amino acids, or polyols, that are included in the formulation to protect the adalimumab protein from physical and chemical degradation during storage and handling. These agents help maintain the protein's correct three-dimensional structure, preventing unfolding, aggregation, and loss of biological activity.
Citations
[1] Samsung Bioepis Co., Ltd. (2015). Pharmaceutical composition comprising adalimumab and method for preparing the same (Korean Patent KR20150102960). Korean Intellectual Property Office.
